🔴 First Tracks Biotherapeutics is trading 5% down in pre-market

First Tracks Biotherapeutics is trading 5.05% lower at $30.08 in pre-market, with no fresh catalyst established.

• No new company announcement dated October 14 was found.
• The latest major news was positive Phase 1b Cohort 1 data for ANB033, announced October 12. The stock closed down 6.96% on October 13, a move one market listing described as giving back part of Monday’s rally.
• Supplied broad-market indicators were modestly positive and do not explain the pre-market decline.